While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end report that it's in a stronger position going into 2025 thanks to improved ...